Sareum granted US patent on autoimmune therapeutic candidate
Sareum Holdings
26.50p
16:55 13/09/24
Clinical-stage biotechnology company Sareum Holdings announced on Monday that it has received a notice of allowance from the US Patent and Trademark Office (USPTO) for its patent on SDC-1801, a dual TYK2/JAK1 kinase inhibitor.
FTSE AIM All-Share
745.23
17:09 13/09/24
Pharmaceuticals & Biotechnology
22,959.13
16:44 13/09/24
The AIM-traded firm said SDC-1801 was being developed as a potential therapeutic for a range of autoimmune diseases.
It said the US patent would provide significant protection for the chemical structure of SDC-1801 and its analogue, their use in treating inflammatory diseases, and certain methods of their chemical synthesis.
The patent approval in the US followed similar protections granted by the European Patent Office, China National Intellectual Property Administration, and Japan Patent Office, securing Sareum's intellectual property across major global territories.
Sareum said it anticipated that the US patent would be formally granted by the end of 2024, pending the completion of standard formalities with the USPTO.
“We are pleased to extend the patent protection for SDC-1801 on the back of the encouraging data from our phase 1a trial, indicating our inhibitor could confer significant advantages over other TYK2/JAK1 kinase inhibitors,” said chief scientific officer Dr John Reader.
“We remain motivated in progressing SDC-1801 through clinical development to develop new therapeutics for autoimmune diseases and cancers.”
At 1110 BST, shares in Sareum Holdings were up 10.71% at 31p.
Reporting by Josh White for Sharecast.com.